APA (7th ed.) Citation

Dimopoulos, M. A., Tedeschi, A., Trotman, J., García-Sanz, R., Macdonald, D., Leblond, V., . . . Buske, C. (2018). Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia. The New England journal of medicine, 378(25), 2399-2410. https://doi.org/10.1056/NEJMoa1802917

Chicago Style (17th ed.) Citation

Dimopoulos, Meletios A., et al. "Phase 3 Trial of Ibrutinib Plus Rituximab in Waldenström’s Macroglobulinemia." The New England Journal of Medicine 378, no. 25 (2018): 2399-2410. https://doi.org/10.1056/NEJMoa1802917.

MLA (9th ed.) Citation

Dimopoulos, Meletios A., et al. "Phase 3 Trial of Ibrutinib Plus Rituximab in Waldenström’s Macroglobulinemia." The New England Journal of Medicine, vol. 378, no. 25, 2018, pp. 2399-2410, https://doi.org/10.1056/NEJMoa1802917.